Xiuling Li

Xiuling Li is an experienced scientist specializing in biologics engineering and antibody development. Currently serving as Associate Director at AstraZeneca since April 2021, Xiuling Li leads a team focused on novel multispecific modalities and oversees pipeline projects from discovery to IND filing. Prior to this role, positions at Pfizer involved leading cross-functional teams to develop therapeutic antibodies and conducting antibody humanization and engineering. Experience at The Scripps Research Institute included constructing phage display libraries and developing antibody-drug conjugates. Earlier roles included research on thromboxane A2 receptor signaling at the University of Kentucky, where Xiuling Li also earned a Ph.D. in Pharmaceutical Sciences with a focus on Cancer Biology, complemented by a Master's in Biochemistry and Molecular Biology and a Bachelor's in Medicinal and Pharmaceutical Chemistry from Sichuan University.